Migraine has emerged as the unexpected GLP-1 secondary indication. AAN 2026 published two large analyses on this site: a 22,000-patient comparative study showing GLP-1 agonists cut migraine ED visits 10% and hospitalizations 14% versus topiramate, and a 10,997-patient cohort showing GLP-1 users were 42% less likely to start CGRP monoclonal antibodies and 48% less likely to start valproate over 12 months.
The mechanism overlap is suggestive — GLP-1 receptors sit on cerebral vascular tissue and trigeminal pathways. Whether the effect is independent of weight loss is the next question several follow-on registry analyses are trying to answer.
Stories here cover the AAN data, follow-on cohort work, and any prospective trials that emerge. See #cgrp for the migraine target class and #neurology for related work.
A second post-hoc analysis of STEP UP presented Tuesday found Wegovy 7.2 mg delivered consistent weight loss across reproductive life stages: 22.6% premenopausal, 19.7% perimenopausal, 19.8% postmenopausal, with 41.4% of premenopausal women hitting ≥25% loss. Waist-circumference reductions: 17.5%, 15.6%, 15.3% respectively. Separately, a real-world analysis of 34,000+ women showed that those taking Wegovy had a 42-45% lower migraine risk and a 25% lower depression risk starting six months in versus those on menopausal hormone therapy alone. The real-world data lands as observational signals that warrant prospective study — not as proof of causation — but reinforces the cardiovascular and quality-of-life narrative for the women's-health subgroup.
A presentation at the American Academy of Neurology 2026 meeting (closing April 22) reported that in 10,997 chronic migraine patients initiating GLP-1 agonists versus an equal topiramate cohort, GLP-1 users were 10% less likely to visit the ED (23.7% vs 26.4%), 14% less likely to be hospitalized, 42% less likely to start CGRP monoclonal antibodies, and 48% less likely to start valproate over 12 months — adding migraine to the growing list of GLP-1 secondary benefits.
New data shows the first oral CGRP antagonist ubrogepant demonstrates better efficacy when administered during mild pain rather than waiting for moderate-to-severe migraine pain.
Retrospective study found combining CGRP monoclonal antibodies with gepants is a safe and well-tolerated dual-mechanism migraine prevention approach.
Retrospective cohort study showed significant migraine frequency reduction with favorable safety for patients with comorbid MS taking CGRP-targeted treatments.